Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK inks £2.5bn shingles vaccine deal with China's Zhifei
03:12am, Monday, 09'th Oct 2023
GSK PLC (LSE:GSK, NYSE:GSK) has inked an exclusive three-year agreement, £2.5 billion with China's Zhifei to co-promote its shingles vaccine in China. With an option for extension, this strategic d
GSK signs shingles vaccine deal with China's Zhifei for about $3 bln
02:18am, Monday, 09'th Oct 2023
GSK , on Monday, announced an exclusive partnership with China's Chongqing Zhifei Biological Products (Zhifei) for its shingles vaccine.
GSK reportedly set to shake up R&D opertion
02:14am, Monday, 09'th Oct 2023
GSK PLC (LSE:GSK, NYSE:GSK) is set to restructure its research division, impacting scientists in the UK, the US, and Belgium, according to the Sunday Times. The pharmaceutical giant aims to replace it
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
10:32am, Friday, 06'th Oct 2023
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Nobel for mRNA: Which other biotech stocks might be overlooked?
08:33am, Friday, 06'th Oct 2023
Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA v
GSK banks almost £900m for Haleon stake sale
03:03am, Friday, 06'th Oct 2023
GSK PLC (LSE:GSK, NYSE:GSK) has further reduced its stake in consumer health group Haleon PLC (LSE:HLN, NYSE:HLN), offloading 270 million shares for around £886 million. It is the second time in thre
GSK raises 886 mln pounds from Haleon stake sale
02:20am, Friday, 06'th Oct 2023
British drugmaker GSK on Friday said it raised 885.6 million pounds ($1.08 billion) from a stake sale in its spun-off consumer healthcare business Haleon at 328 pence a piece.
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
01:31pm, Wednesday, 04'th Oct 2023
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
7 ‘Smart Money' Stocks Set to Explode Higher
03:58pm, Saturday, 30'th Sep 2023
In the dynamic world of investing, there's always a buzz surrounding “smart money” stocks. This excitement isn't just about fleeting market trends; it's rooted in the savvy market decisions made b
GSK: Strong Positioning And Trading At Historical Discount
02:27pm, Friday, 29'th Sep 2023
GSK is a leading biopharmaceutical company with a focus on vaccines and products for major diseases. GSK's drug line-up is safe and profitable, with competitors facing larger sales loss exposure due t
GSK lifts growth ambitions for HIV business on long-acting drug
09:05am, Thursday, 28'th Sep 2023
GSK on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and treating
Explainer: What you need to know about RSV and the new vaccines
12:29pm, Friday, 22'nd Sep 2023
Advisers to the U.S. Centers for Disease Control and Prevention (CDC) are meeting on Friday to discuss recommendations for use of the first vaccine for respiratory syncytial virus (RSV) approved for p
Merck Vs. GSK: The Game-Changer Race In Pharma Excellence
12:14pm, Friday, 22'nd Sep 2023
Despite the increasing number of emerging challenges for the pharmaceutical industry, the management teams at GSK and Merck are successfully coping with them. GSK's revenue was $9.12 billion in the se
GSK's HIV-prevention drug Apretude approved by European Commission
07:19am, Tuesday, 19'th Sep 2023
The European Commission (EC) has authorised GSK PLC (LSE:GSK, NYSE:GSK) subsidiary ViiV Healthcare's HIV-prevention drug Apretude. Known scientifically as cabotegravir, Apretude can be used in combina
European Commission authorises GSK's HIV prevention drug
02:37am, Tuesday, 19'th Sep 2023
The European Commission has authorised GSK's HIV-focused unit ViiV Healthcare's cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.
